[Replication inhibitors targeting early events in the HIV-1 life cycle].
Most of the compounds currently used for treatment of HIV-1 infection are reverse transcriptase inhibitors and protease inhibitors. Several early steps in the HIV-1 life cycle such as virus attachment to host cell and cell-virus fusion are potential targets for drugs. Since most of the target molecules involved in this infection step are cellular, it is expected that the drug resistant mutations occur less frequently than those against viral enzymes. In this review, new inhibitors of entry and fusion are summarized that are promising.
Ichiyama
Kozi
K
Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University.
Yamamoto
Naoki
N
D019380:Anti-HIV Agents / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D015195:Drug Design; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015700:HIV Envelope Protein gp41 / Q000502:physiology; D015497:HIV-1 / Q000254:growth & development*; D006801:Humans; D011485:Protein Binding / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D014779:Virus Replication / Q000187:drug effects*
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D019718:Receptors, CXCR4